In the above article, the term E3 ubiquitin-protein ligase was incorrectly added after CDKN2A. On page 918, in Box 3, the following sentence is incorrect: When MYC is overexpressed, the tumour suppressor p53 is activated, predominantly through CDKN2A (E3 ubiquitin-protein ligase; also known as p14ARF), which in turn interacts with and antagonizes MDM2, the negative regulator of p53 (REF. 125) (see the table). The sentence should read: When MYC is overexpressed, the tumour suppressor p53 is activated, predominantly through CDKN2A (also known as p14ARF), which in turn interacts with and antagonizes MDM2, the negative regulator of p53 (REF. 125) (see the table).
